Comparison between Goldline Pharmaceutical IPO and Highness Microelectronics IPO.
Goldline Pharmaceutical IPO is a SME Bookbuilding IPO proposed to list at BSE SME while Highness Microelectronics IPO is a SME Bookbuilding proposed to list at BSE SME.
| Goldline Pharmaceutical IPO | Highness Microelectronics IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | BSE SME | BSE SME |
| Lead Managers | Cumulative Capital Pvt.Ltd. | Fintellectual Corporate Advisors Pvt.Ltd. |
| Registrar | Bigshare Services Pvt.Ltd. | Skyline Financial Services Pvt.Ltd. |
| Market Maker | Rainbow Securities Pvt.Ltd. | |
| DRHP | DRHP  | DRHP |
| RHP | RHP | |
| Final Prospectus | Final Prospectus | |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL |
The total issue size of Goldline Pharmaceutical IPO is up to ₹0.00 Cr whereas the issue size of the Highness Microelectronics IPO is up to ₹20.58 Cr. The final issue price of Goldline Pharmaceutical IPO is and of Highness Microelectronics IPO is ₹120.00 per share.
| Goldline Pharmaceutical IPO | Highness Microelectronics IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹114.00 per share | |
| Issue Price (Upper) | ₹120.00 per share | |
| Issue Price (Final) | ₹120.00 per share | |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 1200 shares | |
| Fresh Issue Size | 30,00,000 shares | 15,62,400 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹18.75 Cr |
| OFS Issue Size | 0 shares | 1,52,400 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹1.83 Cr |
| Issue Size Total | 30,00,000 shares | 17,14,800 shares |
| Issue Size Total (Amount) | up to ₹0.00 Cr | up to ₹20.58 Cr |
Goldline Pharmaceutical IPO opens on , while Highness Microelectronics IPO opens on Mar 24, 2026. The closing date of Goldline Pharmaceutical IPO and Highness Microelectronics IPO is , and Mar 27, 2026, respectively.
| Goldline Pharmaceutical IPO | Highness Microelectronics IPO | |
|---|---|---|
| Anchor Bid Date | Mar 23, 2026 | |
| Issue Open | Mar 24, 2026 | |
| Issue Close | Mar 27, 2026 | |
| Basis Of Allotment (Tentative) | Mar 30, 2026 | |
| Initiation of Refunds (Tentative) | Apr 01, 2026 | |
| Credit of Share (Tentative) | Apr 01, 2026 | |
| Listing date (Tentative) | Apr 02, 2026 | |
| Anchor Lockin End date 1 | May 01, 2026 | |
| Anchor Lockin End date 2 | Jun 30, 2026 |
Goldline Pharmaceutical IPO P/E ratio is , as compared to Highness Microelectronics IPO P/E ratio of 16.7.
| Goldline Pharmaceutical IPO | Highness Microelectronics IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)Goldline Pharmaceutical Ltd.'s revenue increased by 19% and profit after tax (PAT) rose by 57% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 79.70 | 99.90 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 64.96 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 16.7 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹61.96 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 35.84 | 47.09 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 38.46 | 42.09 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 1.50 | 0.74 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹7.19 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 27.38 | 47.09 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Goldline Pharmaceutical IPO Retail Individual Investors (RII) are offered 0 shares while in Highness Microelectronics IPO retail investors are offered 0 shares. Qualified Institutional Buyers (QIB) are offered 0 shares in Goldline Pharmaceutical IPO and 3,42,000 shares in Highness Microelectronics IPO.
| Goldline Pharmaceutical IPO | Highness Microelectronics IPO | |
|---|---|---|
| Anchor Investor Reservation | 0 shares | 5,11,200 shares |
| Market Maker Reservation | 0 shares | 91,200 shares |
| QIB | 0 shares | 3,42,000 shares |
| NII | 0 shares | 2,59,200 shares |
| RII | 0 shares | 6,02,400 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 0 shares | 17,14,800 shares |
Goldline Pharmaceutical IPO subscribed in total, whereas Highness Microelectronics IPO subscribed 136.11x.
| Goldline Pharmaceutical IPO | Highness Microelectronics IPO | |
|---|---|---|
| QIB (times) | 81.95x | |
| NII (times) | 362.12x | |
| Big NII (times) | 437.22x | |
| Small NII (times) | 211.92x | |
| RII (times) | 185.11x | |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 136.11x |
